Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Hepatic pyruvate kinase. Regulation by glucagon, cyclic adenosine 3'-5'-monophosphate, and insulin in the perfused rat liver.

Open access
Blair, J B, Cimbala, M A, Foster, J L, Morgan, R A · 1976 · Journal of Biological Chemistry

Abstract

A reversible interconversion of two kinetically distinct forms of hepatic pyruvate kinase regulated by glucagon and insulin is demonstrated in the perfused rat liver. The regulation does not involve the total enzyme content of the liver, but rather results in a modulation of the substrate dependence. The forms of pyruvate kinase in liver homogenates are distinguished by measurements of the ratio of the enzyme activity at a subsaturating concentration of P-enolpyruvate (1.3 mM) to the activity at a saturating concentration of this substrate (6.6 mM). A low ratio form of pyruvate kinase (ratio between 0.1 and 0.2) is obtained from livers perfused with 10(-7) M glucagon or 0.1 mM adenosine 3':5'-monophosphate (cyclic AMP). A high ratio form of the enzyme is obtained from livers perfused with no hormone (ratio = 0.35 to 0.45). The regulation of pyruvate kinase by glucagon and cyclic AMP occurs within 2 min following the hormone addition to the liver. Insulin (22 milliunits/ml) counteracts the inhibition of pyruvate kinase caused by 5 X 10(-11) M glucagon, but has only a slight influence on the enzyme properties in the absence of the hyperglycemic hormone. The low ratio form of pyruvate kinase obtained from livers perfused with glucagon or cyclic AMP is unstable in liver extracts and will revert to a high ratio form within 10 min at 37 degrees or within a few hours at 0 degrees. Pyruvate kinase is quantitatively precipitated from liver supernatants with 2.5 M ammonium sulfate. This precipitation stabilizes the enzyme and preserves the kinetically distinguishable forms. The kinetic properties of the two forms of rat hepatic pyruvate kinase are examined using ammonium sulfate precipitates from the perfused rat liver. At pH 7.5 the high ratio form of the enzyme has [S]0.5 = 1.6 +/- 0.2 mM P-enolpyruvate (n = 8). The low ratio form of enzyme from livers perfused with glucagon or cyclic AMP has [S]0.5 = 2.5 +/- 0.4 mM P-enolpyruvate (n = 8). The modification of pyruvate kinase induced by glucagon does not alter the dependence of the enzyme activity on ADP (Km is approximately 0.5 mM ADP for both forms of the enzyme). Both forms are allosterically modulated by fructose 1,6-bisphosphate, L-alanine, and ATP. The changes in the kinetic properties of hepatic pyruvate kinase which follow treating the perfused rat liver with glucagon or cyclic AMP are consistent with the changes observed in the enzyme properties upon phosphorylation in vitro by a clyclic AMP-stimulated protein kinase (Ljungström, O., Hjelmquist, G. and Engström, L. (1974) Biochim. Biophys. Acta 358, 289--298). However, other factors also influence the enzyme activity in a similar manner and it remains to be demonstrated that the regulation of hepatic pyruvate kinase by glucagon and cyclic AMP in vivo involes a phosphorylation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0021-9258(17)33408-7

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Figures

FıG. 1 Insulin reversal of the glucagon inhibition of hepatic pyruvate kinase. Livers from fed rats were perfused for 60 min as an equilibration period. At 60 min a liver sample was excised and glucagon was added to the perfusate to give a final concentration of 5 × 10-11M. Five minutes later another liver sample was excised and either 22 milliunits/ml of insulin (- - -) or a control vehicle (OO) was added to the perfusate. Additional liver samples were taken as shown in the figure. Pyruvate kinase was assayed at 1.3 and 6.6 mm P-enolpyruvate. The ratio of the activity of the enzyme at 1.3 mm P-enolpyruvate to that found at 6.6 mm P-enolpyruvate is shown. The data represent the mean ± S.D. of six perfusions: three livers receiving glucagon followed by insulin and three livers receiving glucagon followed by the control vehicle.
FıG. 1 Insulin reversal of the glucagon inhibition of hepatic pyruvate kinase. Livers from fed rats were perfused for 60 min as an equilibration period. At 60 min a liver sample was excised and glucagon was added to the perfusate to give a final concentration of 5 × 10-11M. Five minutes later another liver sample was excised and either 22 milliunits/ml of insulin (- - -) or a control vehicle (OO) was added to the perfusate. Additional liver samples were taken as shown in the figure. Pyruvate kinase was assayed at 1.3 and 6.6 mm P-enolpyruvate. The ratio of the activity of the enzyme at 1.3 mm P-enolpyruvate to that found at 6.6 mm P-enolpyruvate is shown. The data represent the mean ± S.D. of six perfusions: three livers receiving glucagon followed by insulin and three livers receiving glucagon followed by the control vehicle.CC-BY · From the PDF
FiG. 2 Dependence of pyruvate kinase activity on P-enolpyruvate. A high ratio form of pyruvate kinase (●, O) was prepared from the liver of a fed rat perfused with no hormone treatment and a low ratio form of the enzyme (▲, ∆) was prepared from a liver perfused with 0.1 mm cyclic AMP. Pyruvate kinase was partially purified by centrifuging liver homogenates at 100,000 × g for 30 min and precipitating the, enzyme by bringing the supernatant to 2.5 M ammonium sulfate with the solid salt. The precipitated protein which contains the enzyme was washed twice with 2.5 M ammonium sulfate and was stored as a suspension in this solution. The activity of each enzyme preparation was determined at the indicated concentrations of P-enolpyruvate (PEP) and is expressed as units per mg of protein in the precipitate. Assays were conducted at pH 7.5 with 2.5 mm ADP (●, ▲) and at pH 7.1 (O, ∆) in a medium similar to that described by Taunton et al. (9). The assay medium at pH 7.1 contained 10 mm triethanolamineHCl, 10 mM Na₂ADP, 10 mM MgCl₂, 203 mM KCl, 0.16 mM NADH, and 3.2 units/ml of lactate dehydrogenase. The assays for pyruvate kinase were conducted with the same enzyme preparations for the two conditions shown. Each point represents the average of duplicate determinations.
FiG. 2 Dependence of pyruvate kinase activity on P-enolpyruvate. A high ratio form of pyruvate kinase (●, O) was prepared from the liver of a fed rat perfused with no hormone treatment and a low ratio form of the enzyme (▲, ∆) was prepared from a liver perfused with 0.1 mm cyclic AMP. Pyruvate kinase was partially purified by centrifuging liver homogenates at 100,000 × g for 30 min and precipitating the, enzyme by bringing the supernatant to 2.5 M ammonium sulfate with the solid salt. The precipitated protein which contains the enzyme was washed twice with 2.5 M ammonium sulfate and was stored as a suspension in this solution. The activity of each enzyme preparation was determined at the indicated concentrations of P-enolpyruvate (PEP) and is expressed as units per mg of protein in the precipitate. Assays were conducted at pH 7.5 with 2.5 mm ADP (●, ▲) and at pH 7.1 (O, ∆) in a medium similar to that described by Taunton et al. (9). The assay medium at pH 7.1 contained 10 mm triethanolamineHCl, 10 mM Na₂ADP, 10 mM MgCl₂, 203 mM KCl, 0.16 mM NADH, and 3.2 units/ml of lactate dehydrogenase. The assays for pyruvate kinase were conducted with the same enzyme preparations for the two conditions shown. Each point represents the average of duplicate determinations.CC-BY · From the PDF
FiG. 3 P-enolpyruvate dependence of pyruvate kinase in the presence of 15 μM fructose 1,6-bisphosphate. Ammonium sulfate precipitates containing the high ratio form of pyruvate kinase (●, ▲) and the low ratio form of the enzyme (O, ∆) were prepared from a liver perfused with no hormone treatment and a liver perfused with 1.4 × 10-7 M glucagon, respectively, as described in the legend of Fig. 2. Assays were conducted at pH 7.5 with 2.5 mm ADP and the indicated concentrations of P-enolpyruvate (PEP). The P-enolpyruvate dependence was examined in the absence (▲, ∆) and in the presence (, O) of 15 μm fructose 1,6-bisphosphate. Each point represents the average of duplicate determinations.
FiG. 3 P-enolpyruvate dependence of pyruvate kinase in the presence of 15 μM fructose 1,6-bisphosphate. Ammonium sulfate precipitates containing the high ratio form of pyruvate kinase (●, ▲) and the low ratio form of the enzyme (O, ∆) were prepared from a liver perfused with no hormone treatment and a liver perfused with 1.4 × 10-7 M glucagon, respectively, as described in the legend of Fig. 2. Assays were conducted at pH 7.5 with 2.5 mm ADP and the indicated concentrations of P-enolpyruvate (PEP). The P-enolpyruvate dependence was examined in the absence (▲, ∆) and in the presence (, O) of 15 μm fructose 1,6-bisphosphate. Each point represents the average of duplicate determinations.CC-BY · From the PDF
FiG. 4 Inhibition of pyruvate kinase by L-alanine and ATP. A high ratio form (●, ▲) and a low ratio form (O, ∆) of pyruvate kinase were prepared as described in the legend of Fig. 2. Assays were conducted at pH 7.5 with 2.5 mm ADP and either 4.8 mm P-enolpyruvate (PEP) (O, ) or 6.9 mm P-enolpyruvate (∆, ▲). The inhibition by various concentrations of L-alanine is shown in A and by various concentrations of ATP is presented in B. Each point represents the average of duplicate determinations.
FiG. 4 Inhibition of pyruvate kinase by L-alanine and ATP. A high ratio form (●, ▲) and a low ratio form (O, ∆) of pyruvate kinase were prepared as described in the legend of Fig. 2. Assays were conducted at pH 7.5 with 2.5 mm ADP and either 4.8 mm P-enolpyruvate (PEP) (O, ) or 6.9 mm P-enolpyruvate (∆, ▲). The inhibition by various concentrations of L-alanine is shown in A and by various concentrations of ATP is presented in B. Each point represents the average of duplicate determinations.CC-BY · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Research works printed but not linked: 4

  1. Cimbala, 1975, Fed. Proc., 34, 618
  2. Balinsky, 1975, 3, 919
  3. Cardenas, 1975, 1, 523
  4. Badwey, 1975, 1, 509

Cited by

See all 170

Metadata

Authors
Blair, J. B., Cimbala, M. A., Foster, J. L., & Morgan, R. A.
Affiliations
West Virginia University (US)
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
1976-06
Volume
251
Issue
12
Pages
3756-3762
ISSN
0021-9258 (ISSN-L)
OpenAlex
W1544747395
Cited by
170
References
24
Citations by year
2025: 3 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 1 · 2016: 2 · 2015: 1 · 2014: 2 · 2013: 1 · 2012: 2
FWCI
9.62
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Biological Chemistry (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • American Diabetes Association
  • West Virginia University
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
Keywords
hepatic enzyme regulation, glucagon, cyclic AMP, insulin, isozymes, substrate dependence, enzyme kinetics, ammonium sulfate precipitation, enzyme stability, perfused rat liver, gluconeogenesis, glycogenolysis, glucose-6-phosphate, fructose-1,6-bisphosphate, glucose-1-phosphate
MeSH terms
Cyclic AMP, Adenosine Triphosphate, Alanine, Animals, Fasting, Glucagon, Insulin, Kinetics, Liver, Male, Perfusion, Phosphoenolpyruvate, Pyruvate Kinase, Time Factors, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hepatic pyruvate kinase. Regulation by glucagon, cyclic adenosine 3'-5'-monophosphate, and insulin in the perfused rat liver. https://app.cochat.ai/papers/10.1016/s0021-9258(17)33408-7
The paper
Blair, J. B., Cimbala, M. A., Foster, J. L., & Morgan, R. A. (1976). Hepatic pyruvate kinase. Regulation by glucagon, cyclic adenosine 3'-5'-monophosphate, and insulin in the perfused rat liver. Journal of Biological Chemistry. https://doi.org/10.1016/s0021-9258(17)33408-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.